Avidity Biosciences (RNA) News Today $35.95 +1.39 (+4.02%) Closing price 04:00 PM EasternExtended Trading$36.25 +0.30 (+0.83%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory SubmissionJuly 28 at 9:00 AM | prnewswire.comBrokerages Set Avidity Biosciences, Inc. (NASDAQ:RNA) PT at $66.35July 28 at 4:57 AM | americanbankingnews.comUniversal Beteiligungs und Servicegesellschaft mbH Boosts Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)July 28 at 3:47 AM | marketbeat.comNeo Ivy Capital Management Cuts Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)July 27 at 5:07 AM | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Stock Price Up 9.6% - Still a Buy?July 26 at 3:10 PM | marketbeat.comAvidity (RNA) Jumps 9.2% on Drug Candidate’s Breakthrough Therapy DesignationJuly 26 at 2:34 PM | msn.comAvidity Biosciences stock rises after FDA grants Breakthrough Therapy statusJuly 24, 2025 | investing.comAvidity Biosciences shares climb after FDA grants Breakthrough Therapy designationJuly 24, 2025 | msn.comAvidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 SkippingJuly 23, 2025 | prnewswire.comAvidity Biosciences, Inc. (NASDAQ:RNA) Given Consensus Rating of "Buy" by AnalystsJuly 21, 2025 | marketbeat.comNew York State Common Retirement Fund Purchases 87,468 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)July 20, 2025 | marketbeat.comAvidity Biosciences: Three Accelerated Approval Shots Feels ExcessiveJuly 14, 2025 | seekingalpha.comAvidity Biosciences (NASDAQ:RNA) Shares Gap Up - Here's WhyJuly 14, 2025 | marketbeat.comAvidity Biosciences price target raised to $70 from $60 at Evercore ISIJuly 12, 2025 | msn.comAlps Advisors Inc. Has $2.58 Million Position in Avidity Biosciences, Inc. (NASDAQ:RNA)July 12, 2025 | marketbeat.comAvidity Biosciences, Inc. (RNA) Balance Sheet - Yahoo FinanceJuly 11, 2025 | finance.yahoo.comAvidity Biosciences (NASDAQ:RNA) Coverage Initiated by Analysts at The Goldman Sachs GroupJuly 10, 2025 | marketbeat.comMirae Asset Global Investments Co. Ltd. Boosts Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)July 6, 2025 | marketbeat.comAvidity Biosciences, Inc. (RNA) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.com7RNA : Expert Outlook: Avidity Biosciences Through The Eyes...June 27, 2025 | benzinga.comAvidity Biosciences (NASDAQ:RNA) Receives "Overweight" Rating from Cantor FitzgeraldJune 27, 2025 | marketbeat.comAvidity Biosciences’ SWOT analysis: innovative RNA therapies stock faces pivotal yearJune 26, 2025 | investing.comAvidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Rating of "Buy" from AnalystsJune 26, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Earns Outperform Rating from Analysts at Sanford C. BernsteinJune 24, 2025 | marketbeat.comAvidity, Dyne get Bernstein ratings as oligonucleotide muscle trials advanceJune 24, 2025 | investing.comSG Americas Securities LLC Takes $516,000 Position in Avidity Biosciences, Inc. (NASDAQ:RNA)June 23, 2025 | marketbeat.comAvidity Biosciences’ SWOT analysis: innovative RNA firm eyes 3-drug launch by 2027June 20, 2025 | investing.comAvidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells $27,548.64 in StockJune 19, 2025 | insidertrades.comAvidity Biosciences, Inc. (NASDAQ:RNA) Insider Kathleen P. Gallagher Sells 911 SharesJune 18, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Trading Up 4.1% - Here's WhyJune 17, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Coverage Initiated at Wolfe ResearchJune 17, 2025 | marketbeat.comAvidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potentialJune 16, 2025 | investing.comAvidity Biosciences (NASDAQ:RNA) Shares Down 3.5% - Here's What HappenedJune 16, 2025 | marketbeat.comAssenagon Asset Management S.A. Increases Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)June 15, 2025 | marketbeat.comRhumbline Advisers Increases Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)June 14, 2025 | marketbeat.comGAMMA Investing LLC Has $1.96 Million Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA)June 14, 2025 | marketbeat.comW. Michael Flanagan Sells 20,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) StockJune 12, 2025 | marketbeat.comLeerink Partnrs Has Pessimistic View of RNA FY2026 EarningsJune 12, 2025 | marketbeat.comRaymond James Initiates Coverage of Avidity Biosciences (RNA) with Strong Buy RecommendationJune 12, 2025 | msn.comAvidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond JamesJune 11, 2025 | msn.comAvidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research CongressJune 11, 2025 | prnewswire.comCantor Fitzgerald Weighs in on RNA FY2026 EarningsJune 11, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Coverage Initiated by Analysts at Raymond JamesJune 11, 2025 | marketbeat.com1RNA : The Analyst Verdict: Avidity Biosciences In The Eyes Of 12 ExpertsJune 10, 2025 | benzinga.comCitigroup Increases Avidity Biosciences (NASDAQ:RNA) Price Target to $75.00June 10, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Stock Price Expected to Rise, Barclays Analyst SaysJune 10, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst SaysJune 10, 2025 | marketbeat.comAvidity Biosciences stock falls following positive trial dataJune 10, 2025 | investing.comAvidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease TrialJune 9, 2025 | finance.yahoo.comAvidity Biosciences (NASDAQ:RNA) Stock Price Expected to Rise, Bank of America Analyst SaysJune 9, 2025 | marketbeat.com Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address RNA Media Mentions By Week RNA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RNA News Sentiment▼0.681.07▲Average Medical News Sentiment RNA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RNA Articles This Week▼108▲RNA Articles Average Week Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Genmab A/S News Today Moderna News Today Dr. Reddy's Laboratories News Today QIAGEN News Today Viatris News Today Ascendis Pharma A/S News Today Verona Pharma PLC American Depositary Share News Today BridgeBio Pharma News Today Blueprint Medicines News Today Roivant Sciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RNA) was last updated on 7/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.